Dr. Krolewski heads the Section on Genetics and Epidemiology and is a Professor of Medicine at Harvard Medical School. He received his M.D. and Ph.D. from Warsaw Medical University in Poland. He obtained training in diabetes research at Joslin Diabetes Center and in molecular human genetics at Massachusetts Institute of Technology. Drawing upon the large Joslin Clinic patient population, Dr. Krolewski has established a world-renowned multi-disciplinary research laboratory that combines epidemiologic, genetic and proteomic methods to study the causes of kidney complications (diabetic nephropathy) in Type 1 and Type 2 diabetes and how to diagnose and treat them.
His current research encompasses three areas:
First, development of a new model of early diabetic nephropathy. In large follow-up studies of Joslin Clinic patients, he discovered a new stage of diabetic nephropathy. His discovery changed the established paradigm of early nephropathy, creating a new model that highlights early progressive renal decline, instead of the previously emphasized microalbuminuria, as the primary stage of diabetic nephropathy to be diagnosed and treated to reduce risk of end-stage renal disease.
Second, search for biomarkers of progressive renal decline. Using biobanks of specimens established in his multiple follow-up studies, he examines blood and urinary profiles of proteins, metabolites and microRNAS that are associated with risk of renal decline. This research aims to discover new therapeutic targets to prevent/treat renal decline and find prognostic biomarkers to identify patients at risk of renal function loss. One discovery so far is that high serum uric acid concentration is a determinant of early renal decline. This led to the PERL multi-center clinical trial that tests whether lowering serum uric acid can reduce the rate of renal decline. Another discovery is that elevated serum concentrations of TNFR1 is a strong independent predictor of early and late renal decline. The test based on this discovery will soon be available in clinical practice.
Third, search for susceptibility genes for nephropathy. Dr. Krolewski is the leader in research on genetics of diabetic nephropathy. As one of the PIs of the multination JDRF Collaborative Research Initiative on Genetics of Diabetic Nephropathy, he leads the effort to identify genes that specifically increase the risk of progressive renal decline leading to end-stage renal disease.
Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes:
Full text: http://stm.sciencemag.org/cgi/content/full/13/600/eabd2699?ijkey=JGEBNGZE5OUvM&keytype=ref&siteid=scitransmed
Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of End Stage Kidney Disease in Diabetes
Effect of TNFα stimulation on expression of kidney risk inflammatory proteins in human umbilical vein endothelial cells cultured in hyperglycemia
Erratum. Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. Diabetes Care
A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders